Fig. 4.
Immunogenicity of the CEA694–702L2 peptide analog in HLA-A*0201 colon cancer patients and tumor reactivity of CD8+ T-cell clones. a PBMCs from three HLA-A2 colon cancer patients were stimulated with 10 μg/ml of peptide and cultured for 10 days in 1,000 IU/ml IL-2. FluMA58–66 and NY-ESO-1157–165 peptides were used as controls of peptide-specific CTL induction. Cells were labeled with the indicated A2 multimer and anti-CD8 mAb. Data is summarized in Table 3. b CEA694–702WT and CEA694–702L2 peptide recognition efficiency of the 18 patient-derived CTL clones generated from A2/CEA694–702 multimers-guided cell sorting and limiting dilution. c Tumor-cell recognition of tumor cell lines expressing CEA antigen. Left panel shows CD8+ T-cell functional avidity of polyclonal and clonal populations. Center panel presents histograms of tumor recognition in chromium release assay unpulsed or pulsed with CEA694–702 peptide. Right panel shows CTL recognition of tumor cells unpulsed or pulsed with CEA694–702 peptide but pre-treated for 72 h with IFN-γ